Spots Global Cancer Trial Database for Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Official Title: Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Study ID: NCT01380587
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.
Detailed Description: Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital Universitario Dr. Jose E. Gonzalez UANL, Monterrey, Nuevo Leon, Mexico
Contact Details
Name: Cesar H Gutierrez Aguirre, MD
Affiliation: Hospital Universitario Dr. Jose E. Gonzalez UANL
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
